TELO
Telomir Pharmaceuticals, Inc.
Key Financials
Net Income
$-10413205
↑ 37.0%
Operating Income
$2.2M
N/A
Total Liabilities
$1.4M
↑ 109.7%
Cash & Equivalents
$754323.00
N/A
Shareholders' Equity
$5.9M
↑ 819.6%
Total Assets
$7.3M
↑ 454.5%
EPS (Diluted)
$-0.33
↓ 158.9%
Operating Cash Flow
$-3688188.00
↑ 27.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/10/2026 | View on SEC |
| DEF 14A | 7/28/2026 | View on SEC |
| 4 | 7/27/2026 | View on SEC |
| 4 | 7/27/2026 | View on SEC |
| 4 | 7/27/2026 | View on SEC |
| 8-K | 6/15/2026 | View on SEC |
| 3 | 6/9/2026 | View on SEC |
| 8-K | 6/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TELO |
| Company Name | Telomir Pharmaceuticals, Inc. |
| CIK | 1971532 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | FL |
| Phone | 786-396-6723 |